Sigyn Therapeutics faces going-concern with $459 cash and $5.49M liabilities

Sigyn Therapeutics, Inc. (PINK: SIGY)

Short take: the company is a development-stage medical device firm with no revenue, mounting losses and very limited cash. Management is funding operations mainly with convertible debentures, preferred-share inducements and small financings; the balance sheet shows severe liquidity stress and a going-concern warning.

Key facts & statistics
* Cash at June 30, 2025: $459 (down from $12,144 at Dec. 31, 2024).
* Total assets: $51,759; Total liabilities: $5,489,388; Stockholders' deficit: $(5,437,629).
* Accumulated deficit: $(16,801,475) at June 30, 2025.
* Working capital deficit: $5,487,629 (as noted in filing).
* Net loss: $(2,119,751) six months ended June 30, 2025; $(1,451,187) three months ended June 30, 2025.
* Net loss per share (basic & diluted): $(1.32) six months; $(0.90) three months (weighted avg shares: 1,605,377).
* Six‑month operating expenses: $1,015,572 (down from $1,232,774 Y/Y).
* Six‑month R&D: $16,323 (vs $473,022 prior-year six months) - large decrease.
* Stock-based compensation: $100,000 (six months); $50,000 (three months).
* "Other" expense (six months): $1,104,179 - includes inducement of preferred shares $845,901 and warrant modification $17,505.
* Convertible notes payable, net: $2,307,986 (gross convertible notes reported $2,489,705).
* Regulation D offering: 69 Units sold totaling $379,717 (cash received $345,197) as of June 30, 2025.
* Net cash used in operating activities (six months): $(446,882); net cash from financing: $435,197; net change in cash: $(11,685).
* Shares outstanding as of filing date (Sept 5, 2025): 1,605,377.

What's happening inside the company (concise)
* Management is prioritizing capital raises via convertible debentures, Regulation D Units and promissory notes to fund clinical and development activities.
* The company recorded a large non‑cash inducement charge ($845,901) for issuing Series B preferred shares to encourage conversions/investment - this materially increased "other expense."
* R&D spending has been cut sharply year-over-year for the six‑month period (from $473k to $16k), suggesting a pause/slowdown in direct development spend or reallocation of costs.
* Several convertible notes matured or defaulted; the company states it is negotiating extensions/restructures with major holders (Osher, Brio).
* Lease for San Diego office was terminated May 15, 2025; security deposit treatment and termination payments recorded.

Positive aspects of the income statement
* Operating expenses decreased six months Y/Y (1,015,572 vs 1,232,774), showing cost reduction efforts.
* R&D expense materially declined (six months: $16,323 vs $473,022), which preserves cash near-term (but may slow development).
* Management continues to secure financing (convertible notes, Regulation D Units) to bridge near-term cash needs.

Negative aspects of the income statement
* No revenues since inception - the company remains pre-revenue.
* Large net losses: $(2.12M) for six months - company is burning cash and recognizing non‑operating financing charges.
* "Other expense" is high and driven by inducement of preferred shares $845,901 plus accretion/amortization of debt discounts and original issue costs (interest-like charges totaling hundreds of thousands). These are recurring financing costs that inflate losses.
* Extremely low cash balance ($459) vs large current liabilities ($5.49M) - severe liquidity mismatch and substantial doubt about going concern.

Risks and near‑term triggers to watch
* Ability to restructure or extend convertible note maturities (Osher, Brio) - defaults could accelerate debt actions.
* Success of ongoing/expected financings (Reg D, convertible note programs, Lambda tranche referenced in subsequent events) to prevent insolvency.
* FDA regulatory path and timing for IDE/first‑in‑human studies - delays increase cash burn and funding needs.
* Potential dilution from automatic conversions, warrants and preferred-share conversions if financings convert or listings occur.

Bottom line
Sigyn (PINK: SIGY) is a pre‑revenue, development‑stage device company with promising technical ambitions but acute financial stress. The filing shows active financing and cost cuts, but large non‑cash financing charges, defaults/near‑defaults on notes, almost-zero cash and a going‑concern disclosure. Investors should treat the equity as highly speculative and monitor near‑term financings, note restructurings and clinical/IDE progress for any change in the liquidity trajectory.